^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KIM1 expression

i
Other names: KIM1, Kidney injury molecule 1, HAVCR1, Hepatitis A virus cellular receptor 1, T-cell immunoglobulin mucin family member 1, TIM-1, T cell immunoglobin domain and mucin domain protein 1
Entrez ID:
Related biomarkers:
5d
In situ detection of PD1-PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC. (PubMed, J Thorac Oncol)
Our study proposes a diagnostic shift from static biomarker quantification to assessing active immune pathways, providing more precise ICI treatment. This functional concept applies to tiny lung biopsies and can be used to further immune checkpoints. Accordingly, our results indicate concerted ICI resistance mechanisms, highlighting a need for combination diagnostics and therapies.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • KIM1 (Kidney injury molecule 1) • FCRL1 (Fc Receptor Like 1)
|
PD-L1 expression • EGFR mutation • PD-1 expression • KIM1 expression
10d
Aloe arborescens Standardized Glycosidic Fraction Suppresses Hepatocarcinoma by Modulating TIMP1, MMP9 Genes Expression, and Inflammation/Ki67/TGFβ1 Pathway. (PubMed, Phytother Res)
This study revealed that AAG exhibited a marked suppressive effect on HCC cell proliferation, displaying a range of mechanistic actions, including decreasing the metabolic activation of cytochrome enzymes, which consequently reduced the production of reactive oxygen species and other genes implicated in cancer development. AAG could be a significant therapeutic candidate for patients diagnosed with hepatocarcinoma.
Journal
|
AFP (Alpha-fetoprotein) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
KIM1 expression
19d
Adipose mesenchymal stem cell conditioned medium and extract: A promising therapeutic option for regenerative breast cancer therapy. (PubMed, SAGE Open Med)
Human adipose-derived mesenchymal stem cells-derived SUP and CE exhibit antitumor effects on breast cancer cells, suggesting a potential therapeutic strategy to suppress tumor progression. Mesenchymal stem cells-SUP and CE could be a safe and novel regenerative approach for breast reconstruction postmastectomy without tumor recurrence risk.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • CASP9 (Caspase 9) • THY1 (Thy-1 membrane glycoprotein) • ENG (Endoglin)
|
BAX expression • KIM1 expression
24d
Activation of the HIF1α/TIMP1/MT6-MMP pathway is associated with invasion in pituitary null cell adenomas. (PubMed, Endocr Relat Cancer)
Regarding the molecular mechanism, HIF1α overexpression could down-regulated TIMP1 and up-regulated MT6-MMP expression levels but not affected EMT markers expression. Our results suggested HIF1α might contribute to the invasion of pituitary null cell adenomas through activating HIF1α/TIMP1/MT6-MMP pathway but not EMT.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
HIF1A overexpression • HIF1A expression • KIM1 expression
1m
A comprehensive analysis of gene expression and the immune landscape in gastric cancer through single-cell and multi-omics approaches. (PubMed, Discov Oncol)
Moreover, new insights into the expression levels of AGT, INHBA, and TIMP1 showed distinct sex-biased gene functions within the tumor microenvironment. These findings enhance our understanding of the molecular mechanisms associated with gastric cancer development and may lay the groundwork for identifying novel therapeutic targets and diagnostic strategies.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression
2ms
Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1. (PubMed, Signal Transduct Target Ther)
In addition, we found that EV and TIMP1 could inhibit Notch1 and downstream targets Hes1, P16, P21, and P53. Collectively, our data suggests that both AMSC-EV and HUMSC-EV attenuate skin photoaging through TIMP1/Notch1.
Journal
|
NOTCH1 (Notch 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • HES1 (Hes Family BHLH Transcription Factor 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TIMP1 overexpression • KIM1 expression • TIMP1 expression
2ms
The circRNA circSCAF8 promotes tumor growth and metastasis of gastric cancer via miR-1293/TIMP1signaling. (PubMed, Gene Ther)
Subsequent rescue experiments revealed that TIMP1 overexpression reversed the impact of circSCAF8 shRNA viruses on gastric cancer. In conclusion, circSCAF8 expression was elevated in gastric cancer, and circSCAF8 shRNA viruses inhibited gastric cancer growth and metastasis by upregulating TIMP1 expression via miR-1293.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • MIR1293 (MicroRNA 1293)
|
TIMP1 overexpression • KIM1 expression • TIMP1 expression • miR-1293 expression
2ms
Gene-expression profile analysis to disclose diagnostics and therapeutics biomarkers for thyroid carcinoma. (PubMed, Comput Biol Chem)
Then we detected 6 repurposable drug molecules (Entrectinib, Imatinib, Ponatinib, Sorafenib, Retevmo, and Pazopanib) by molecular docking with KGs-mediated receptor proteins, ADME/T analysis, and cross-validation with the independent receptors. Therefore, these findings might be useful resources for wet lab researchers and clinicians to consider an effective treatment strategy against THCA.
Journal • Gene Expression Profile
|
TOP2A (DNA topoisomerase 2-alpha) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • RUNX2 (RUNX Family Transcription Factor 2)
|
KIM1 expression • TIMP1 expression
|
sorafenib • Rozlytrek (entrectinib) • imatinib • Iclusig (ponatinib) • pazopanib • Retevmo (selpercatinib)
2ms
Tim-1-mediated extracellular matrix promotes the development of hepatocellular carcinoma. (PubMed, Acta Biochim Biophys Sin (Shanghai))
Further studies demonstrate that Tim-1 mediates the activation of hepatic stellate cells and upregulates Th1 and Th2 cytokines, thereby promoting HCC progression. Thus, Tim-1 may represent a novel target for future interventions in HCC and liver fibrosis.
Journal
|
KIM1 (Kidney injury molecule 1)
|
KIM1 expression
3ms
Exercise preconditioning mitigates brain injury after cerebral ischemia-reperfusion injury in rats by restraining TIMP1. (PubMed, Immun Inflamm Dis)
Altogether, exercise preconditioning had protective effects on CIRI by restraining TIMP1, which provided new therapeutic strategies for preventing CIRI.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • CASP3 (Caspase 3) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression • TIMP1 expression
3ms
Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer. (PubMed, Biochem Genet)
Specifically, CA724 is noticeably elevated in IBD, while the levels of CEA, RUNX1 with TIMP1 are probable genes that may be employed in discerning IBD progression to CRC. Therefore, these preliminary results once validated in large patient cohorts could potentially have a significant impact on CRC disease stratification, resulting in a more precise prediction for treatment and treatment outcomes, especially in South African patients.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CA 19-9 (Cancer antigen 19-9) • RELA (RELA Proto-Oncogene)
|
KIM1 expression
4ms
High expression of ABL2 promotes gastric cancer cells migration, invasion and proliferation via the TGF-β and YAP signaling pathways. (PubMed, J Cancer)
Furthermore, GA-017 increased ABL2 expression in MGC-803 cells and counteracted the effects of si-ABL2 on cell migration, invasion and proliferation. These findings indicated that heightened ABL2 expression could activate TGF-β/SMAD2/3 and YAP signaling pathway, promoting epithelial mesenchymal transformation (EMT), and enhancing multiplication, metastasis, and invasion in GC cells.
Journal
|
MMP2 (Matrix metallopeptidase 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase) • TGFB1 (Transforming Growth Factor Beta 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
|
KIM1 expression • TIMP1 expression • PCNA expression
4ms
Clinicopathological and prognostic significance of TIMP1 expression in gastric cancer: a systematic review and meta-analysis. (PubMed, Expert Rev Anticancer Ther)
Furthermore, TIMP1 expression was associated with poor prognosis in GC patients. TIMP1 expression was related to tumor differentiation and poor prognosis but not sex, age, TNM stage, depth of invasion, lymph node metastasis or tumor size.
Retrospective data • Review • Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression • TIMP1 expression
4ms
METTL3-mediated TIM1 promotes macrophage M1 polarization and inflammation through IGF2BP2-dependent manner. (PubMed, J Biochem Mol Toxicol)
Besides, knockdown of METTL3/IGF2BP2 suppressed LPS-induced macrophage M1 polarization and inflammation, while this effect could be eliminated by TIM1 overexpression. METTL3/IGF2BP2/TIM1 axis promoted macrophage M1 polarization and inflammation, which might provide potential target for sepsis treatment.
Journal
|
IL6 (Interleukin 6) • MUC1 (Mucin 1) • TNFA (Tumor Necrosis Factor-Alpha) • KIM1 (Kidney injury molecule 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • CD86 (CD86 Molecule) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3)
|
IGF2 overexpression • KIM1 expression
8ms
Repurposing homoharringtonine for thyroid cancer treatment through TIMP1/FAK/PI3K/AKT signaling pathway. (PubMed, iScience)
Mechanistically, HHT exerted anti-TC effects by downregulating TIMP1 expression and then inactivating the FAK/PI3K/AKT signaling pathway. Taken together, our study demonstrated that HHT could inhibit TC progression by inhibiting the TIMP1/FAK/PI3K/AKT signaling pathway.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
TIMP1 overexpression • KIM1 expression • TIMP1 expression
|
Synribo (omacetaxine mepesuccinate)
8ms
Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms. (PubMed, Aging (Albany NY))
In summary, this study uncovers the immune gene expression patterns in COAD, establishes a robust prognostic model, and elucidates the molecular mechanisms and potential therapeutic targets for COAD liver metastasis, thereby possessing significant theoretical and clinical implications. These findings are anticipated to offer substantial support for both the treatment and prognosis management of COAD patients.
Journal • Gene Signature • IO biomarker
|
CAV1 (Caveolin 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • ANXA1 (Annexin A1) • LARS2 (Leucyl-TRNA Synthetase 2) • CALB2 (Calbindin 2)
|
KIM1 expression
8ms
Megalin-related mechanism of hemolysis-induced acute kidney injury and the therapeutic strategy. (PubMed, J Pathol)
Collectively, cilastatin-mediated selective megalin blockade is an effective therapeutic strategy to prevent both heme-mediated PTEC injury and cast formation in hemolysis-induced AKI.
Journal
|
KIM1 (Kidney injury molecule 1)
|
KIM1 expression
9ms
Screening of differentially expressed genes in gastric cancer based on GEO database and function and pathway enrichment analysis (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
SPARC, TIMP1, THBS2 and other DEGs are probably involved in GC occurrence and progression and may serve as potential candidate molecular markers for early diagnosis and prognostic evaluation of GC.
Journal
|
SPARC (Secreted Protein Acidic And Cysteine Rich) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • THY1 (Thy-1 membrane glycoprotein) • COL6A3 (Collagen Type VI Alpha 3 Chain) • TFF1 (Trefoil Factor 1) • THBS2 (Thrombospondin 2)
|
KIM1 expression • TIMP1 expression
9ms
Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. (PubMed, EBioMedicine)
We discovered regulatory B cell-like CD38+ B cell infiltration as an independent prognostic factor in PDAC. The use of CD38 inhibitor may provide new possibilities for PDAC immunotherapy.
Clinical data • Journal • IO biomarker
|
CD5 (CD5 Molecule) • IL10 (Interleukin 10) • GZMB (Granzyme B) • KIM1 (Kidney injury molecule 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
KIM1 expression
10ms
Comprehensive analysis of basement membrane-related gene based on single-cell and bulk RNA sequencing data to predict prognosis and evaluate immune characteristics in colorectal cancer. (PubMed, Environ Toxicol)
Our study has discovered a novel prognostic index derived from BM-related genes in CRC patients. Specifically, the new model enables patient stratification, improving the selection of individuals likely to benefit from immunotherapy.
Journal • IO biomarker
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
TIMP1 overexpression • KIM1 expression • TIMP1 expression
11ms
Benzophenone-3 alters expression of genes encoding vascularization and epithelial-mesenchymal transition functions during Trp53-null mammary tumorigenesis. (PubMed, Food Chem Toxicol)
Among the genes altered in expression, Timp1 is of particular interest because benzophenone-3 suppressed both migration and Timp1 expression in a mammary tumor cell line that displays epithelial to mesenchymal transition characteristics. These alterations in gene expression plausibly stabilize the vasculature of epithelial carcinomas and contribute to benzophenone-3 promotion of epithelial tumors, while at the same time suppress epithelial to mesenchymal transition and suppress incidence of spindle cell tumors.
Journal
|
TP53 (Tumor protein P53) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression • TIMP1 expression
11ms
TIMP1/CHI3L1 facilitates glioma progression and immunosuppression via NF-κB activation. (PubMed, Biochim Biophys Acta Mol Basis Dis)
In addition, TIMP1 resulted in immunosuppressive macrophage polarization. In summary, TIMP1/CHI3L1 might be perceived as a diagnostic marker and an immunotherapy target for gliomas.
Journal • IO biomarker
|
CHI3L1 (Chitinase 3-like 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TAGLN (Transgelin) • CASP4 (Caspase 4)
|
KIM1 expression • TIMP1 expression
11ms
The Role of Zuo Jin Wan in Modulating the Tumor Microenvironment of Colorectal Cancer. (PubMed, Comb Chem High Throughput Screen)
ZJW regulates a range of cells in the CRC microenvironment, including malignant CRC, immune cells, and stromal cells. In CRC cell lines, downregulation of TIMP1 and MTDH by ZJW may play an important role in the immunomodulation in CRC.
Journal • IO biomarker
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • TLR4 (Toll Like Receptor 4) • MTDH (Metadherin)
|
KIM1 expression • TIMP1 expression
11ms
Astrocytic TIMP-1 regulates production of Anastellin, an inhibitor of oligodendrocyte differentiation and FTY720 responses. (PubMed, Proc Natl Acad Sci U S A)
Last, analyses of proteomic databases of MS samples identified Ana peptides to be more abundant in the cerebrospinal fluid (CSF) of human MS patients with high disease activity. A role for Ana in MS as a consequence of a lack of astrocytic TIMP-1 production could influence both the efficacy of fingolimod responses and innate remyelination potential in the MS brain.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
KIM1 expression • TIMP1 expression
|
fingolimod
12ms
Single-cell N-methyladenosine-related genes function within the tumor microenvironment to affect the prognosis and treatment sensitivity in patients with gastric cancer. (PubMed, Cancer Cell Int)
Our study visualized the cellular heterogeneity of TME at the single-cell level, revealed the association between mA mRNA modification and intracellular communication, clarified MRGs as an independent risk factor of prognosis, and provided a reference for follow-up treatment.
Journal
|
CAV1 (Caveolin 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • GJA1 (Gap Junction Protein Alpha 1) • IGFBP3 (Insulin-like growth factor binding protein 3) • COL4A1 (Collagen Type IV Alpha 1 Chain)
|
KIM1 expression
1year
Transcription Factor FOSL1 Promotes Angiogenesis of Colon Carcinoma by Regulating the VEGF Pathway Through Activating TIMP1. (PubMed, Biochem Genet)
FOSL1 activated VEGF pathway by up-regulating TIMP1 expression, thereby advancing CC angiogenesis. We provided theoretical basis that the FOSL1/TIMP1/VEGF pathway might be a novel option for anti-angiogenesis therapy of CC.
Journal
|
KDR (Kinase insert domain receptor) • FLT4 (Fms-related tyrosine kinase 4) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • FOSL1 (FOS Like 1)
|
KDR expression • FOSL1 expression • VEGFA expression • KIM1 expression • TIMP1 expression
1year
Integration of single-cell transcriptomics and epigenetic analysis reveals enhancer-controlled TIMP1 as a regulator of ferroptosis in colorectal cancer. (PubMed, Genes Genomics)
Transcription of TIMP1 was driven by transcription factor SPI1 in combination with its enhancer, consequently promoting CRC cells against ferroptosis. The SPI1/TIMP1 axis confers ferroptosis resistance in CRC, and thus has the potential to be the molecular targets for CRC treatment.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • SPI1 (Spi-1 Proto-Oncogene) • DUOX2 (Dual Oxidase 2) • ETV4 (ETS Variant Transcription Factor 4)
|
KIM1 expression • TIMP1 expression
|
RSL3
1year
Spatial landscape of melanoma brain metastases with and without pre-surgical immune checkpoint blockade (SNO 2023)
Such data suggest these cells might also increase immunosuppressive interactions with T cells. In summary, our study reveals how ICB affects the spatial architecture and crosstalk of different cell types within melanoma brain metastases and will provide insights into new therapeutic strategies for brain metastases patients.
Checkpoint inhibition • Checkpoint block
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • MMP9 (Matrix metallopeptidase 9) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • MRC1 (Mannose Receptor C-Type 1)
|
CXCL9 expression • KIM1 expression • TIMP1 expression
1year
Pilot Study on the Molecular Pathogenesis of Pyeloureteral Junction Obstruction: Underdevelopment or Fibrosis? (PubMed, Medicina (Kaunas))
These findings suggest that tissue fibrosis, similar to other tissues and organs, is not the leading cause of stenosis, at least at the moment of surgery. Decreased CTGF expression is indicative of the developmental origin of obstruction.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1) • TGFB1 (Transforming Growth Factor Beta 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • MMP1 (Matrix metallopeptidase 1) • CTGF (Connective tissue growth factor)
|
KIM1 expression • PAI1 expression
1year
Unraveling TIMP1: a multifaceted biomarker in colorectal cancer. (PubMed, Front Genet)
Drug sensitivity analysis, conducted using the DepMap database, revealed that colorectal cancer cell lines exhibiting elevated levels of TIMP1 expression were more responsive to certain drugs, such as CC-90003, Pitavastatin, Atuveciclib, and CT7001, compared to those with low levels of TIMP1. Furthermore, TIMP1 expression was positively correlated with that of ferroptosis-related genes, such as GPX4 and HSPA5. TIMP1 can be used as a biomarker for colorectal cancer and is associated with the immunological microenvironment, drug sensitivity, and ferroptosis inhibition in this disease.
Journal • IO biomarker
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • SPP1 (Secreted Phosphoprotein 1) • GPX4 (Glutathione Peroxidase 4) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • MMP1 (Matrix metallopeptidase 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • MMP3 (Matrix metallopeptidase 3)
|
TIMP1 overexpression • KIM1 expression • TIMP1 expression
|
samuraciclib (CT7001) • CC-90003 • atuveciclib (BAY 1143572) • pitavastatin
1year
Maternal Exposure to Tetrahydrocannabinol (THC) During Pregnancy Increases Kidney Damage in Mouse Offspring (KIDNEY WEEK 2023)
Our findings suggest that maternal exposure to THC during pregnancy may increase the risk of kidney damage in offspring. These results highlight the need for further research on the potential long-term effects of cannabis use during pregnancy.
Preclinical
|
KIM1 (Kidney injury molecule 1)
|
KIM1 expression
1year
THE IPS-DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE (AASLD 2023)
Our results indicated that iMSCs ameliorated fibrosis and fatty deposition in the liver and improved liver functions. The exosome derived from iMSCs was also crucial factor to improve liver environment. Our iMSCs will be the new cell source for the treatment for NAFLD/MAFLD related cirrhotic patients
Preclinical
|
TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • TGFB1 (Transforming Growth Factor Beta 1) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • FGF21 (Fibroblast Growth Factor 21) • MMP9 (Matrix metallopeptidase 9) • ATF6 (Activating Transcription Factor 6) • XBP1 (X-box-binding protein 1)
|
KIM1 expression
over1year
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KRAS G12D • KRAS G12 • KIM1 expression • TIMP1 expression
over1year
Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer. (PubMed, Genome Med)
This data provides a rich resource for deeper studies of gastrointestinal malignancies. Newly identified splicing isoform TIMP1 Δ4-5 plays an important role in mediating CRC progression and may be a potential therapy target in CRC.
Journal
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression • TIMP1 expression
over1year
TIMP1 shapes an immunosuppressive microenvironment by regulating anoikis to promote the progression of clear cell renal cell carcinoma. (PubMed, Aging (Albany NY))
ARGs played crucial roles in tumorigenesis and progression and were positively associated with a poor prognosis. AI had great accuracy in predicting the prognosis and immune characteristics of ccRCC patients. TIMP1 was significantly associated with clinicopathological variables and the immunosuppressive microenvironment, which could be exploited to design novel immunotherapies for ccRCC patients.
Journal • IO biomarker
|
TIMP1 (Tissue inhibitor of metalloproteinases 1)
|
KIM1 expression
over1year
Spatial transcriptomics reveals heterogeneity of macrophages in the tumor microenvironment of granulomatous slack skin. (PubMed, J Pathol)
Our data shed light on the characteristics of macrophages in the GSS microenvironment and provide a theoretical basis for the application of MMP9 inhibitors to prevent cutaneous relaxation of GSS.
Journal
|
CD163 (CD163 Molecule) • SPP1 (Secreted Phosphoprotein 1) • CHI3L1 (Chitinase 3-like 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL2 (Chemokine (C-C motif) ligand 2) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • APOE (Apolipoprotein E) • ITGAX (Integrin Subunit Alpha X) • MRC1 (Mannose Receptor C-Type 1) • ZFP36 (ZFP36 Ring Finger Protein)
|
KIM1 expression
over1year
Identification of a Diagnosis and Therapeutic Inflammatory Response-Related Gene Signature Associated with Esophageal Adenocarcinoma. (PubMed, Crit Rev Eukaryot Gene Expr)
The receiver operating characteristic curve indicated that GNA15, MXD1, NOD2, PLAUR and TIMP1 expression had a performed well in diagnosing EAC from healthy control. GNA15, MXD1, NOD2, PLAUR and TIMP1 were identified and validated as novel potential biomarkers for early diagnosis and may be new molecular targets for treatment of EAC.
Journal • Gene Signature
|
CD4 (CD4 Molecule) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • PLAUR (Plasminogen Activator, Urokinase Receptor)
|
KIM1 expression • TIMP1 expression